Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma (HCC).

9 Jun 2014

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

New vaccine effective at preventing lung cancer in mice

Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.

4 Jun 2014

Researchers develop antibodies that reduce liver damage, recovers liver function

A Tainan-based research team from National Cheng Kung University (NCKU) has discovered the pathogenesis of liver fibrosis and developed antibodies that reduce liver damage, inhibit hepatic fibrosis, and recover liver function.

4 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions.

16 May 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development.

9 May 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is on the verge of becoming an epidemic among Mexican Americans, especially in Texas.

8 May 2014

Snacking linked with abdominal fat and fatty liver

Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis).

7 May 2014

Liver cancer screening in cirrhosis patients improves survival rates

Liver cancer survival rates could be improved if more people with cirrhosis are screened for tumors using inexpensive ultrasound scans and blood tests, according to a review by doctors at UT Southwestern Medical Center.

6 May 2014

Study: New combination therapy to treat chronic hepatitis C

A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient.

5 May 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

UMC Utrecht and Quirem Medical team up to develop holmium microspheres for liver cancer

Over the next few years, the University Medical Center Utrecht and Quirem Medical will be working closely together to maximize the benefits of using holmium microspheres to treat liver cancer patients worldwide. The unique properties of holmium microspheres will enable effective treatment planning, dosimetry en treatment evaluation, thereby further improving the results of patients who undergo radioembolization.

25 Apr 2014

Researchers launch detailed atlas with environment and health maps

Researchers have launched a detailed atlas with environment and health maps at a fine scale across England and Wales.

25 Apr 2014

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

Liver Cancer News and Research

Further Reading

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

New vaccine effective at preventing lung cancer in mice

Researchers develop antibodies that reduce liver damage, recovers liver function

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

U.S. urges daily pill for those at risk of AIDS

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Hepatocellular carcinoma on the rise among Mexican Americans

Snacking linked with abdominal fat and fatty liver

Liver cancer screening in cirrhosis patients improves survival rates

Study: New combination therapy to treat chronic hepatitis C

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

UMC Utrecht and Quirem Medical team up to develop holmium microspheres for liver cancer

Researchers launch detailed atlas with environment and health maps

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

New data focuses on different approaches to improve diagnosis and treatment of HCC

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News